Mar 27, 2015
The U.S. Food and Drug Administration (FDA) has officially greenlighted Regeneron’s EYLEA® (aflibercept) Injection to treat Diabetic Retinopathy in Patients with Diabetic Macular Edema (DME) which marks the fourth approved indication for the drug in...
Mar 25, 2015
AstraZeneca will enter into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) in order to acclimatize a technique for the creation of human beta cells from stem cells for use in screens of AstraZeneca’s compound...
Mar 20, 2015
Daiichi Sankyo, Inc has partnered with AstraZeneca to co-commercialize MOVANTIK™ (naloxegol) in the US which is a once-daily oral PAMORA specifically designed for the treatment of OIC in adult patients with chronic non-cancer pain.
Mar 19, 2015
Eli Lilly has entered into an exclusive license agreement with Hanmi Pharmaceutical Co., Ltd. to develop and commercialize Hanmi's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of autoimmune and other diseases.
Mar 17, 2015
The Dementia Discovery Fund has been established by the UK government to fuel research and development for Dementia which pose a serious threat to public health and healthcare systems globally according to the World Health Organization.
Mar 13, 2015
Bayer HealthCare striving for strong sales and margin growth through 2017!
Mar 10, 2015
The U.S. Food and Drug Administration (FDA) has approved Unituxin (dinutuximab) from the United Therapeutics Corporation as a part of first-line therapy for pediatric patients with high-risk neuroblastoma.
Mar 05, 2015
In an effort to expand their presence in the oncology market and expand their already resilient pipeline, Abbvie will acquire Pharmacyclics including its blockbuster product Imbruvica, a first class BTK inhibitor approved for hematologic...
Mar 03, 2015
Shire has submitted a New Drug Application (NDA) with the U. S. Food and Drug Administration for a novel small-molecule integrin inhibitor called Lifitegrast to treat dry eye disease symptoms in adults.
Feb 26, 2015
The U.S. Food and Drug Administration (FDA) has approved Sanofi’s Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, intended to improve the glycemic index in adults living with type 1 and type 2...